NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free PHAT Stock Alerts $10.09 -0.01 (-0.10%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$9.68▼$11.1550-Day Range$7.77▼$12.0552-Week Range$6.07▼$17.02Volume1.11 million shsAverage Volume809,858 shsMarket Capitalization$590.51 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Phathom Pharmaceuticals alerts: Email Address Phathom Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside118.0% Upside$22.00 Price TargetShort InterestBearish43.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 16 Articles This WeekInsider TradingSelling Shares$191,641 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.22) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector540th out of 915 stocksPharmaceutical Preparations Industry248th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted43.45% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 12.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 1.9 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,641.00 in company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.22) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesApril 11, 2024 | insidertrades.comMolly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockMay 10, 2024 | investorplace.comThe 3 Best Healthcare Stocks to Buy in May 2024May 10, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 9, 2024 | globenewswire.comPhathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Promising Pipeline DevelopmentsMay 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial OutlookMay 7, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Recommendation for Stoke Therapeutics Amidst Strategic Progress and Anticipated Clinical MilestonesMay 7, 2024 | americanbankingnews.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCMay 10, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 5, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up to $9.76May 5, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Coverage Initiated at Stifel NicolausMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market TrajectoryMay 3, 2024 | msn.comStifel Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy RecommendationMay 2, 2024 | msn.comPeloton stock sinks to record low as CEO steps downMay 2, 2024 | msn.comMiami sports mogul receives $10 billion offer for his assets, here's why he rejected the dealMay 2, 2024 | americanbankingnews.comPhathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on ThursdayApril 29, 2024 | finance.yahoo.comPhathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024April 26, 2024 | markets.businessinsider.comBuy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oqueznaApril 23, 2024 | markets.businessinsider.comNeedham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)April 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oqueznaApril 19, 2024 | finance.yahoo.com12 Most Shorted Stocks in 2024April 12, 2024 | investing.comPhathom Pharmaceuticals CFO sells over $38k in company stockApril 10, 2024 | markets.businessinsider.comBuy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising PipelineApril 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)April 7, 2024 | msn.comPhathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analystApril 6, 2024 | markets.businessinsider.comOptimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data FluctuationsSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees452Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+118.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-29,558.95% Return on EquityN/A Return on Assets-63.40% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.22 Sales & Book Value Annual Sales$680,000.00 Price / Sales868.33 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-7.94Miscellaneous Outstanding Shares58,520,000Free Float44,420,000Market Cap$590.47 million OptionableOptionable Beta0.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Comp: $1.11MMr. David A. Socks (Age 49)Co-Founder & Director Comp: $58.78kDr. Azmi Nabulsi M.D. (Age 65)M.P.H., Co-Founder & COO Comp: $815.21kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Comp: $671.27kDr. Aditya Kohli Ph.D. (Age 35)Co-Founder Comp: $319.65kMr. Lawrence R. Miller Esq.J.D., General Counsel & SecretaryMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial OfficerMore ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSCalliditas Therapeutics AB (publ)NASDAQ:CALTArriVent BioPharmaNASDAQ:AVBPStoke TherapeuticsNASDAQ:STOKAerovate TherapeuticsNASDAQ:AVTEView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemBought 11,228 shares on 5/9/2024Ownership: 0.019%Entropy Technologies LPSold 2,452 shares on 5/8/2024Ownership: 0.021%Jennison Associates LLCBought 1,647,697 shares on 5/2/2024Ownership: 2.816%Klingman & Associates LLCBought 10,376 shares on 5/1/2024Ownership: 0.018%China Universal Asset Management Co. Ltd.Bought 4,363 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions PHAT Stock Analysis - Frequently Asked Questions Should I buy or sell Phathom Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHAT shares. View PHAT analyst ratings or view top-rated stocks. What is Phathom Pharmaceuticals' stock price target for 2024? 5 Wall Street analysts have issued twelve-month target prices for Phathom Pharmaceuticals' stock. Their PHAT share price targets range from $10.00 to $28.00. On average, they anticipate the company's share price to reach $22.00 in the next year. This suggests a possible upside of 118.0% from the stock's current price. View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts. How have PHAT shares performed in 2024? Phathom Pharmaceuticals' stock was trading at $9.13 at the start of the year. Since then, PHAT shares have increased by 10.5% and is now trading at $10.09. View the best growth stocks for 2024 here. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($1.42) EPS for the quarter, topping analysts' consensus estimates of ($1.43) by $0.01. The business had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.76 million. What ETFs hold Phathom Pharmaceuticals' stock? ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED). When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (12.76%), Jennison Associates LLC (2.82%), Entropy Technologies LP (0.02%), State Board of Administration of Florida Retirement System (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and Klingman & Associates LLC (0.02%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHAT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICYou need to know these two things about AI stocks ASAP…InvestorPlaceThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
